Furthermore, recent prolongation of progression-free survival with vorasidenib, an IDH inhibitor, in patients with residual or recurrent IDH-mutant gliomas, may further increase the number of patients with latent disease for senolytic clinical trials130. Here, IDH1 is linked to central nervous system cancer.